Review article: Selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 26-38

  Felice, C ^a,b   Lewis, A ^a   Armuzzi, A ^b   Lindsay, J O ^a   Silver, A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; BELINOSTAT; BUTYRIC ACID; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; ISOENZYME; MICRORNA; MOCETINOSTAT; PANOBINOSTAT; PRACINOSTAT; QUISINOSTAT; RESMINOSTAT; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT; AUTACOID; CYTOKINE; ISOPROTEIN;

ABDOMINAL PAIN; APOPTOSIS; CELL PROLIFERATION; COLITIS; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; EPITHELIAL BARRIER; FATIGUE; GENE CONTROL; HEMATOLOGIC DISEASE; HOMEOSTASIS; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTE DIFFERENTIATION; NAUSEA; NONHUMAN; PERMEABILITY BARRIER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SOMNOLENCE; TRANSCRIPTION REGULATION; VOMITING; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; APOPTOSIS; CYTOKINES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MICE; MICRORNAS; PROTEIN ISOFORMS;

EID: 84915745302     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13008     Document Type: Review

References (76)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
2. Abraham BP, Sellin JH. Disability in inflammatory bowel disease. Gastroenterol Clin North Am 2012; 41: 429-41.
3. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn' s disease: a systematic review. Inflamm Bowel Dis 2013; 19: 429-44.
4. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 490: 119-24.
5. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013; 145: 293-308.
6. Karatzas PS, Gazouli M, Safioleas M, Mantzaris GJ. DNA methylation changes in inflammatory bowel disease. Ann Gastroenterol 2014; 27: 125-32.
7. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903.
8. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-40.
9. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206-18.
10. Reichert N, Choukrallah MA, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 2012; 69: 2173-87.
11. Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27: 4784-95.
12. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003; 160: 1017-27.
13. Qiu T, Zhou L, Zhu W, et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 2013; 9: 255-69.
14. Kawabata T, Nishida K, Takasugi K, et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010; 12: R133.
15. Grausenburger R, Bilic I, Boucheron N, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 2010; 185: 3489-97.
16. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006; 176: 5015-22.
17. Glauben R, Batra A, Stroh T, et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 2008; 57: 613-22.
18. Turgeon N, Moore Gagné J, Blais M, et al. The acetylome regulators Hdac1 and Hdac2 differently modulate intestinal epithelial cell dependent homeostatic responses in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2014; 306: G594-605.
19. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13: 2318-22.
20. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.
21. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-50.
22. Turgeon N, Blais M, Gagnè JM, et al. HDAC1 and HDAC2 restrain the intestinal inflammatory response by regulating intestinal epithelial cell differentiation. PLoS ONE 2013; 8: e73785.
23. Alenghat T, Osborne LC, Saenz SA, et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature 2013; 504: 153-7.
24. Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11: 1-15.
25. Han SB, Lee JK. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch Pharm Res 2009; 32: 613-24.
26. Grabiec AM, Korchynskyi O, Tak PP, et al. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424-31.
27. Vojinovic J, Damjanov N, D'Urzo C, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 1452-8.
28. Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and Sirtuin-1 control FoxP3+ regulatory T cell function through shared and isotype-specific mechanisms. Sci Signal 2012; 5: ra45.
29. Tsaprouni LG, Ito K, Powell JJ, Adcock IM, Punchard N. Differential patterns of histone acetylation in inflammatory bowel diseases. J Inflamm 2011; 8: 1-12.
30. Sealy L, Chalkley R. The effect of sodium butyrate on histone modification. Cell 1978; 14 : 115-21.
31. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA 2014; 111: 2247-52.
32. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003; 33 : 244-8.
33. Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1β, and nuclear factor κB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J 2006; 82: 130-5.
34. Liu Q, Shimoyama T, Suzuki K, Umeda T, Nakaji S, Sugawara K. Effect of sodium butyrate on reactive oxygen species generation by human neutrophils. Scand J Gastroenterol 2001; 36: 744-50.
35. Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403.
36. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006; 281: 13548-58.
37. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005; 12: 395-404.
38. Schwab M, Reynders V, Loitsch S, Steinhilber D, Schröder O, Stein J. The dietary histone deacetylase inhibitor sulforaphane induces human-β-defensin-2 in intestinal epithelial cells. Immunology 2008; 125: 241-51.
39. Cantley MD, Haynes DR. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology 2013; 21: 301-7.
40. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446: 557-61.
41. Mudter J, Weigmann B, Bartsch B, et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in infl ammatory bowel diseases. Am J Gastroenterol 2005; 100: 64-72.
42. Chen L, Fischle W, Verdin E, et al. Duration of NF-kappaB action regulated by reversible acetylation. Science 2001; 293: 1653-7.
43. Glauben R, Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med 2011; 17: 426-33.
44. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-52.
45. Bosisio D, Vulcano M, Del Prete A, et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol 2008; 84: 1540-8.
46. Glauben R, Sonnenberg E, Wetzel M, Mascagni P, Siegmund B. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo. J Biol Chem 2014; 289: 6142-51.
47. Di Sabatino A, Biancheri P, Piconese S, et al. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infl iximab in Crohn 's disease. Inflamm Bowel Dis 2010; 16: 1891-7.
48. Guidi L, Felice C, Procoli A, et al. FOXP3 + T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents. Biomed Res Int 2013; 2013: 286368.
49. Tao R, De Zoeten EF, Özkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-307.
50. Dalal SR, Know JH. The Role of MicroRNA in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 2010; 6: 714-22.
51. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-81.
52. Zhao ZN, Bai JX, Zhou Q, et al. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS ONE 2012; 7: e45133.
53. Wang JH, Shih KS, Wu YW, Wang AW, Yang CR. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1b signalling in osteoarthritis fibroblast-like synoviocytes. Osteoarthritis Cartilage 2013; 21: 1987-96.
54. Cacchiarelli D, Martone J, Girardi E, et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 2010; 12: 341-51.
55. Nijhuis A, Biancheri P, Lewis A, et al. In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci (Lond) 2014; 127: 341-50.
56. Koon JW, Shih DQ, Hing TC, et al. Substance P induces CCN1 expression via histone deacetylase activity in human colonic epithelial cells. Am J Pathol 2011; 179: 2315-26.
57. Kelly RD, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 2013; 41: 741-9.
58. Zimmermann MA, Singh N, Martin PM, et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upergulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1405-15.
59. Chen X, Barozzi I, Termanini A, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci USA 2012; 109: E2865-74.
60. De Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010; 138: 583-94.
61. De Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and Heat Shock Protein 90 control the function of FoxP3+ T-regulatory cells. Mol Cell Biol 2011; 31: 2066-78.
62. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280: 168-76.
63. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-12.
64. Davie JR. Inhibition of histone deacetylase activity in butyrate. J Nutr 2003; 133: 2485S-93S.
65. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409: 581-9.
66. Bieliauskas AV, Pflum MKH. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008; 37: 1402-13.
67. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
68. Arts J, King P, Mariën A, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009; 15: 6841-51.
69. Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 2010; 149: 518-28.
70. Yong WP, Goh BC, Soo RA, et al. Phase I and pharmacodynamic study of an oral administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol 2011; 22: 2516-22.
71. Ravillah D, Mohammed A, Qian L, et al. Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis. J Pharmacol Exp Ther 2014; 348: 59-68.
72. Gillespie J, Savic S, Wong C, et al. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012; 64: 418-22.
73. Wells CE, Bhaskara S, Stengel KR, et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS ONE 2013; 8: e68915.
74. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389-94.
75. Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010; 132: 10842-6.
76. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-89.